These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36994823)

  • 21. Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial.
    Morita A; Strober B; Burden AD; Choon SE; Anadkat MJ; Marrakchi S; Tsai TF; Gordon KB; Thaçi D; Zheng M; Hu N; Haeufel T; Thoma C; Lebwohl MG
    Lancet; 2023 Oct; 402(10412):1541-1551. PubMed ID: 37738999
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Severe flare of generalized pustular psoriasis treated with spesolimab, an IL-36-directed monoclonal antibody.
    Mateeva V; Vasilev P; Gospodinova K; Gincheva V; Shahid M; Kostova P; Lukanov T; Yordanova I
    J Dtsch Dermatol Ges; 2024 May; 22(5):696-699. PubMed ID: 38619312
    [No Abstract]   [Full Text] [Related]  

  • 23. Spesolimab treatment in a patient with generalized pustular psoriasis: a case report with 12-month follow-up and literature review.
    Cardenas-de la Garza JA; Zazueta-López RM; Garza-Elizondo AK; Flores-Gutierrez DP; Welsh E
    Clin Exp Dermatol; 2024 Feb; 49(3):286-288. PubMed ID: 37966307
    [No Abstract]   [Full Text] [Related]  

  • 24. [Remission of recalcitrant generalized pustular psoriasis under interleukin-36 receptor inhibitor spesolimab].
    Müller VL; Kreuter A
    Dermatologie (Heidelb); 2023 May; 74(5):356-359. PubMed ID: 36943426
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A case of acrodermatitis continua of Hallopeau evolving into generalized pustular psoriasis successfully treated with guselkumab.
    Yamamoto H; Kamiya K; Okada H; Maekawa T; Komine M; Ohtsuki M
    Int J Dermatol; 2023 Feb; 62(2):269-270. PubMed ID: 35187654
    [No Abstract]   [Full Text] [Related]  

  • 26. Spesolimab in patients with flare of generalized pustular psoriasis: A multicentre case-series.
    Bellinato F; Gisondi P; Dattola A; Richetta AG; Costanzo A; Valenti M; De Simone C; Marzano AV; Zussino M; Pezzolo E; Nacca M; Pellacani G; Girolomoni G
    J Eur Acad Dermatol Venereol; 2024 May; 38(5):e437-e439. PubMed ID: 38084869
    [No Abstract]   [Full Text] [Related]  

  • 27. Generalized pustular psoriasis recurring during pregnancy and lactation successfully treated with ixekizumab.
    Huang D; Liu T; Li J; Lu Y; Ma H
    Dermatol Ther; 2022 Dec; 35(12):e15878. PubMed ID: 36181408
    [No Abstract]   [Full Text] [Related]  

  • 28. Efficacy and safety of risankizumab in Japanese patients with generalized pustular psoriasis or erythrodermic psoriasis: Primary analysis and 180-week follow-up results from the phase 3, multicenter IMMspire study.
    Yamanaka K; Okubo Y; Yasuda I; Saito N; Messina I; Morita A
    J Dermatol; 2023 Feb; 50(2):195-202. PubMed ID: 36514850
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transcriptomic response of peripheral blood mononuclear cells to secukinumab in an 8-year-old boy with juvenile generalized pustular psoriasis.
    Hou PC; Aala W; Lee YR; Guevara BEK; Chen PC; McGrath JA; Hsu CK
    J Eur Acad Dermatol Venereol; 2022 May; 36(5):e378-e381. PubMed ID: 35023595
    [No Abstract]   [Full Text] [Related]  

  • 30. A case of generalized pustular psoriasis with discrepant resolution time between pustules and erythema after treatment with spesolimab.
    Matsuo M; Niwa H; Onishi H; Iwata H
    J Dermatol; 2024 Apr; 51(4):e127-e128. PubMed ID: 37955351
    [No Abstract]   [Full Text] [Related]  

  • 31. Pustular psoriasis appearing in a Chinese woman treated with dupilumab for atopic dermatitis: A case report.
    Zhong X; Li Y; Gao Y; Zhang Y; Lu J; Yu N; Ding Y; Shi Y
    Dermatol Ther; 2022 Nov; 35(11):e15851. PubMed ID: 36153663
    [No Abstract]   [Full Text] [Related]  

  • 32. Long-term efficacy of ixekizumab in erythrodermic and generalized pustular psoriasis patients.
    Egawa G; Honda T; Kabashima K
    J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):259. PubMed ID: 30746797
    [No Abstract]   [Full Text] [Related]  

  • 33. Spesolimab in the treatment of generalized pustular psoriasis: a critically appraised research paper.
    Ali F; Smith CH; Mahil SK
    Br J Dermatol; 2023 Feb; 188(3):328-329. PubMed ID: 36763745
    [No Abstract]   [Full Text] [Related]  

  • 34. Successful treatment of paediatric generalized pustular psoriasis with secukinumab: a case series.
    Albela H; Begum S; Leong KF
    J Dermatolog Treat; 2022 May; 33(3):1769-1773. PubMed ID: 33706651
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Spesolimab improves patient-reported outcomes in patients with generalized pustular psoriasis: Results from the Effisayil 1 study.
    Navarini AA; Prinz JC; Morita A; Tsai TF; Viguier MA; Li L; Thoma C; Sivalingam M; Lebwohl MG
    J Eur Acad Dermatol Venereol; 2023 Apr; 37(4):730-736. PubMed ID: 36527385
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis.
    Khatri A; Eckert D; Oberoi R; Suleiman A; Pang Y; Cheng L; Othman AA
    J Clin Pharmacol; 2019 Dec; 59(12):1656-1668. PubMed ID: 31257614
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open-label, phase 3 study (UNCOVER-J).
    Okubo Y; Mabuchi T; Iwatsuki K; Elmaraghy H; Torisu-Itakura H; Morisaki Y; Nakajo K
    J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):325-332. PubMed ID: 30317671
    [TBL] [Abstract][Full Text] [Related]  

  • 38. De novo pustular psoriasis associated with dupilumab therapy in a young male with the diagnosis of atopic dermatitis.
    Incel Uysal P; Gunhan O
    Dermatol Ther; 2022 May; 35(5):e15399. PubMed ID: 35194901
    [No Abstract]   [Full Text] [Related]  

  • 39. Increased risk of severe generalized pustular psoriasis due to tuberculosis screening delay for spesolimab initiation.
    Hackley M; Thampy D; Waseh S; Feldman SR; Blauvelt A; Weinberg JM; Schwartzman S; Liao W; Prussick R; Cohen JM; Hsu S;
    J Am Acad Dermatol; 2024 Feb; 90(2):408-410. PubMed ID: 37821053
    [No Abstract]   [Full Text] [Related]  

  • 40. Commentary on a Clinical Trial of Spesolimab, a Humanized Anti-interleukin-36 Receptor Monoclonal Antibody, in Generalized Pustular Psoriasis.
    Shao S; Wang G
    Dermatol Ther (Heidelb); 2022 Dec; 12(12):2627-2635. PubMed ID: 36208408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.